From its first description in 1935 until now, clinical outcomes for patients with cystic fibrosis have undergone a dramatic transformation. While the rare genetic disease was once an early death ...

A drug developer that recently reported positive phase 3 results for its cystic fibrosis treatment for a severe form of the genetic disorder is raising $40 million in equity, according to a Form D ...

Since nonsense mutations play a role in many genetic disorders, including cystic fibrosis and some cancers, this discovery could impact many lives. Comparison of GEN binding in C. albicans and S.

Please provide your email address to receive an email when new articles are posted on . The Cystic Fibrosis Foundation is providing funds to Prime Medicine to advance research on its gene editing ...

After false starts and incremental gains, scientists crack the problem that made breathing impossible. Will answers come fast ...

Award to help fund preclinical studies to apply Specific Biologics' Dualase™ gene editing platform as a potential treatment for cystic fibrosis patients with nonsense genetic mutations. Dualase™ cuts ...

BETHESDA, Md.--(BUSINESS WIRE)--Today, the Cystic Fibrosis Foundation announced an additional investment of up to $24 million in Prime Medicine to continue the development of a gene editing therapy ...

An optimized version of prime editing technology raises the possibility of a one-time treatment for cystic fibrosis. In their 2019 paper, Liu’s team used prime editing to alter the gene mutations ...

Genetic testing plays an important role in cystic fibrosis screening and diagnosis. It can help determine if a person has cystic fibrosis or carries gene mutations that cause it. Other tests can also ...

BETHESDA, Md.--(BUSINESS WIRE)--Today, the Cystic Fibrosis Foundation announced that it will provide up to $15 million to Prime Medicine for preclinical research into gene editing for cystic fibrosis.

Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a combination medicine approved by the FDA in 2024. Alyftrek is approved to treat people ages 6 and older who have ...